Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4052W HIGH $12.37
Volume
73.33 K
Value Traded
90.00 K
Short % Float
1.25%
Days to Cover
2.3
-7.84%Week
-32.54%1 Month
-34.11%3 Month
-40.51%6 Month
-90.51%5 Year
-99.34%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.62 M
EPS (TTM)
-1.44
P/E Ratio
-
Ent. Value
-11.72 M
Total Shares
8.25 M
Float Shares
7.83 M
Insiders
4.98%
Institutions
36.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
LPCN Catalyst Timeline
Dated clinical, regulatory and corporate events for Lipocine Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lipocine Inc.
910Total events
14Upcoming
268Tier-1 (high impact)
2013 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovalTLANDOApprovedFDA Decision
Health Canada approves TLANDO for testosterone replacement therapy
testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism)source ↗
●Trial InitiationTrial
Lipocine initiates BLOOM Phase 3 study of LPCN 1154 in postpartum depression
postpartum depressionsource ↗
▲Other Regulator MilestoneTLANDOApprovedEx-US Regulatory
Pharmalink received marketing authorization approval for TESTYRA (TLANDO) in UAE
hypogonadismsource ↗
▲FDA ApprovalTESTYRAApprovedFDA Decision
Pharmalink received marketing authorization approval for TESTYRA (TLANDO) in UAE
testosterone replacement therapysource ↗
▲Other Regulator MilestoneTESTYRAApprovedEx-US Regulatory
Pharmalink received marketing authorization approval for TESTYRA (TLANDO) in UAE
hypogonadismsource ↗
◆Oral PresentationPresentation
Virtual KOL event highlighting unmet needs in PPD and clinical profile of LPCN 1154
postpartum depressionsource ↗
●Timing GuidancePresentation
505(b)(2) NDA submission for LPCN 1154 expected in mid-2026
postpartum depressionsource ↗
◆Poster PresentationPresentation
Phase 3 data for LPCN 1154 selected for poster presentation at 2026 ASCP Annual Meeting
postpartum depressionsource ↗
●Oral PresentationPresentation
Oral and poster presentations at ASCP Annual Meeting
postpartum depressionsource ↗
◆Oral PresentationPresentation
Lipocine management to present at A.G.P.'s Annual Virtual Healthcare Company Showcase
▼Topline ReadoutClinical Data
Topline results from Phase 3 trial of LPCN 1154 in PPD
postpartum depressionsource ↗
◆Breakthrough Therapy DesignationDesignation
Breakthrough therapy designation application submitted for LPCN 1154 in PPD
postpartum depressionsource ↗
◆Fast Track DesignationDesignation
Fast track designation application submitted for LPCN 1154 in PPD
postpartum depressionsource ↗
▼Topline ReadoutClinical Data
Topline results from Phase 3 trial of LPCN 1154 for PPD
postpartum depressionsource ↗
◆Breakthrough Therapy DesignationDesignation
Applied for breakthrough therapy designation for LPCN 1154 in PPD
postpartum depressionsource ↗
◆Fast Track DesignationDesignation
Applied for fast track designation for LPCN 1154 in PPD
postpartum depressionsource ↗
◆Full ResultsClinical Data
Full analysis of trial data to be completed in coming weeks
postpartum depressionsource ↗
▲Last Patient Last VisitTrial
Last Patient Last Visit in Phase 3 trial of LPCN 1154 for PPD
postpartum depressionsource ↗
▲Enrollment CompleteTrial
Enrollment and dosing completed in Phase 3 trial of LPCN 1154 for PPD
postpartum depressionsource ↗
▲DSMB ReviewTrial
Second interim DSMB safety review completed; recommended trial continue without modification
postpartum depressionsource ↗
▲Milestone PaymentTLANDOApprovedCorporate
License fee payment of $1 million due
testosterone replacement therapysource ↗
▲Product LaunchTLANDOApprovedPost-Market
Verity Pharma planning launch and commercialization of TLANDO in Canada
male hypogonadismsource ↗
▲Enrollment MilestoneTrial
80% enrollment completed in Phase 3 study of LPCN 1154 for PPD
postpartum depressionsource ↗
◆Poster PresentationPresentation
Two LPCN 2101 abstracts accepted for poster presentation at AES 2025
epilepsysource ↗
▲DSMB ReviewTrial
First scheduled DSMB review completed; recommended trial continue without modification
postpartum depressionsource ↗
▲Enrollment UpdateTrial
47 participants have completed dosing; no discontinuations or dose reductions
postpartum depressionsource ↗
◆Poster PresentationPresentation
Poster presentation of 20-week data from Phase 2 trial of LPCN 2401 at ObesityWeek
obesitysource ↗
◆DSMB ReviewTrial
DSMB safety review and safety update planned for 4Q 2025
postpartum depressionsource ↗
▲Enrollment MilestoneTrial
One-third of patients randomized in Phase 3 trial of LPCN 1154
postpartum depressionsource ↗
◆Oral PresentationPresentation
Lipocine management to present at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationPresentation
Lipocine management presentation at H.C. Wainwright 27th Annual Global Investment Conference
●Oral PresentationPresentation
Virtual R&D investor event on LPCN 1154 held on July 9, 2025
postpartum depressionsource ↗
◆R&D DayPresentation
Virtual R&D investor event to discuss LPCN 1154 for PPD
postpartum depressionsource ↗
▲First Patient DosedTrial
First patient dosing targeted for Phase 2 study of LPCN 2401 in obesity
obesitysource ↗
▲First Patient DosedTrial
First patient dosed in Phase 3 trial of LPCN 1154 for postpartum depression
postpartum depressionsource ↗
●NDA SubmissionTLANDOApprovedRegulatory Filing
New Drug Submission filed for TLANDO in Canada
testosterone replacement therapysource ↗
◆PublicationPresentation
Phase 2 results of LPCN 1148 published in Hepatology June 2025 edition
cirrhosis with sarcopeniasource ↗
●NDA SubmissionTLANDOApprovedRegulatory Filing
Verity Pharma filed NDS for TLANDO in Canada
hypogonadismsource ↗
◆Oral PresentationPresentation
Lipocine to present at A.G.P.'s Annual Healthcare Company Showcase
▲Trial InitiationTrial
Initiated outpatient Phase 3 safety and efficacy study of LPCN 1154
postpartum depressionsource ↗
Past FDA Catalysts and PDUFA Decisions
How LPCN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | LPCN 1154 | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 34%
Micro Cap(rank 224 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LPCN 1148 Small moleculeCompletedNCT04874350 | Liver Cirrhosis | Phase 2 | COMPLETED | 30 | Dec 18, 2023 | ||||||
| LPCN 1154A Small moleculeNCT06979544 | Depression, Postpartum | Phase 3 | COMPLETED | 210 | Feb 17, 2026 | ||||||
| LPCN 1144 Small moleculeCompletedNCT04685993 | NASH - Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 25 | Mar 1, 2022 | ||||||
| LPCN 1021 Small moleculeMarketedNCT03242408 | Hypogonadism, Male | Phase 3 | COMPLETED | 333 | Jul 1, 2017 | ||||||
| testosterone undecanoate, LPCN 1021 Small moleculeMarketedNCT02081300 | Male Hypogonadism | Phase 3 | COMPLETED | 315 | May 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every LPCN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LPCN 1154 Fast Track | Postpartum Depression | Phase 3 | 2026-05-07 | N=90; no treatment-related serious adverse events; no cases of excessive sedation or loss of consciousness; no treatment-related discontinuations; n=54Read More | Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Higuchi John W.Director | Buy | 15,970 241,365 held | $2.23 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LPCN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.1 % (-66.7 %) | 1.30 M | 508.56 K |
LPCN Institutional Ownership Trends
LPCN Short Interest
Shares sold short, counted twice a month.
1.25%
Short % of Float
of tradable shares sold short
97.8K
Shares Sold Short
-1.6% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
43.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LPCN ranks across every disease it competes in
Competitive Position is a premium feature
See how LPCN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLPCN News
LPCNLipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
Lipocine Inc. announced that Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with male hypogonadism. This approval, facilitated through Lipocine's partner Verity Pharmaceuticals, allows for a new oral treatment option that simplifies dosing. Verity Pharma is set to launch TLANDO in Canada by the end of 2026, aiming to capture a significant share of the TRT market.
Read more →LPCNLipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Lipocine Inc. has initiated the BLOOM Phase 3 study for LPCN 1154, targeting postpartum depression. The study aims to evaluate the drug's efficacy and safety based on previous findings and FDA feedback. Approximately 120 participants will be enrolled, with dosing expected to start in early Q4 2026. The company is optimistic about the treatment's potential to provide rapid relief.
Read more →LPCNLipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Lipocine Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The presentation is scheduled for September 16 at 10am ET in New York. Investors can register for the conference and access a live webcast of the presentation on Lipocine's website.
Read more →LPCNLipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Lipocine Inc. reported its financial results for Q2 2026, highlighting a net loss of $2.6 million. The company faced challenges with LPCN 1154 for postpartum depression, failing to meet primary trial endpoints, though post hoc analyses indicated potential efficacy. Lipocine plans to conduct further trials and has scheduled a meeting with the FDA for guidance.
Read more →LPCNLipocine Appoints Michael J. Grissinger to Board of Directors
Lipocine Inc. has appointed Michael J. Grissinger to its Board of Directors, effective August 3, 2026. Grissinger brings over two decades of experience from Johnson & Johnson, where he held senior management roles in pharmaceutical licensing and corporate development. His expertise is expected to aid Lipocine in advancing its pipeline and forming strategic partnerships.
Read more →LPCNLipocine to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Lipocine Inc. is hosting a virtual Key Opinion Leader event on June 12, 2026, to discuss ongoing unmet needs in postpartum depression (PPD) and the clinical profile of LPCN 1154, an investigational oral formulation of brexanolone. The webinar will bring together leading physicians to review the current treatment landscape, persistent gaps in care, and present Phase 3 trial results for LPCN 1154. Attendees will explore the potential impact of LPCN 1154 within the PPD treatment paradigm. Advance registration for the event is required and a replay will be available afterward.
Read more →LPCNLipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Lipocine Inc. announced a virtual Key Opinion Leader (KOL) event focusing on postpartum depression (PPD) and its investigational oral treatment, LPCN 1154. Scheduled for June 12, 2026, the webinar will feature expert discussions on PPD's unmet clinical needs and the latest results from Phase 3 trials of LPCN 1154, which aims to provide convenient at-home treatment. The event aims to engage leading physicians and will include a Q&A session for attendees.
Read more →LPCNAnaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
Anaveon has appointed Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer. These appointments aim to enhance the company's leadership and accelerate its clinical development and pipeline expansion in the field of autoimmune and inflammatory diseases. Both executives bring extensive experience in their respective fields, which is expected to drive Anaveon's growth and impact.
Read more →LPCNLipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Lipocine Inc. announced that its Phase 3 clinical data for LPCN 1154 has been accepted for an oral presentation at the 2026 ASCP Annual Meeting. The presentation will focus on LPCN 1154's efficacy in treating postpartum depression. The company highlights the potential of LPCN 1154 to provide rapid symptom relief with minimal side effects.
Read more →LPCNLipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Lipocine Inc. will participate in A.G.P.'s Annual Healthcare Company Showcase on May 20, 2026. The event will feature a fireside chat with management, highlighting Lipocine's innovative oral delivery technology and its drug development pipeline. The company aims to address significant unmet medical needs with its diverse range of drug candidates.
Read more →LPCNLipocine Announces Financial Results for the Quarter Ended March 31, 2026
Lipocine Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a net loss of $3.7 million, an increase from the previous year's loss. The company disclosed that LPCN 1154, under investigation for treating postpartum depression, failed to meet its primary endpoint in a Phase 3 study, despite showing some positive results in a subgroup analysis. Lipocine is currently contemplating its development strategy for LPCN 1154 and has applied for breakthrough therapy and fast track designations with the FDA. The company's cash reserves have grown significantly, providing a stronger financial foundation for future development efforts.
Read more →LPCNLipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Lipocine Inc. reported its financial results for Q1 2026, highlighting the Phase 3 trial results for LPCN 1154, which did not meet its primary endpoint for treating postpartum depression. However, the drug was well tolerated, and significant improvements were noted in a subset of patients. The company is exploring further development options and has applied for breakthrough therapy designation.
Read more →LPCN▼ -77.8%on this newsshared move
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Lipocine Inc. announced topline results from its Phase 3 trial of LPCN 1154 for postpartum depression. The trial did not meet its primary endpoint, showing no significant reduction in HAM-D scores compared to placebo. However, LPCN 1154 was well tolerated, with no serious adverse events reported. The company is exploring further development options and has applied for breakthrough therapy designation.
Read more →LPCNLipocine Announces Financial Results for the Full Year Ended December 31, 2025
Lipocine Inc. announced its financial results for the full year ended December 31, 2025, highlighting a pivotal year for the company. Their revenue fell significantly to $2.0 million from $11.2 million in the previous year, leading to a net loss of $9.6 million. Despite these challenges, Lipocine remains optimistic about its drug developments, particularly its LPCN 1154 therapy for postpartum depression. Furthermore, the company's cash reserves increased to approximately $24.7 million as of March 2026.
Read more →LPCNLipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine Inc. has announced that the last patient completed their final visit in the pivotal Phase 3 trial of LPCN 1154, designed to treat postpartum depression. The trial involved 90 patients and reported a positive safety profile, with no serious side effects noted. The drug's oral formulation aims to provide rapid relief for new mothers suffering from severe postpartum depression, addressing significant existing gaps in treatment options. Data from this trial will support a 505(b)(2) NDA submission expected in 2026.
Read more →LPCN▼ -10.9%on this news
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Inc. has completed enrollment and dosing in its Phase 3 trial for LPCN 1154, an oral treatment for postpartum depression (PPD). The trial involved 90 patients and has shown a favorable safety profile with no serious adverse events reported. Results are anticipated in early Q2 2026, which may support a future NDA submission.
Read more →LPCN▲ +12.7%on this news· ran to +41% by day 3
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Inc. announced positive updates from the second interim safety review of its Phase 3 trial for LPCN 1154, an oral formulation aimed at treating postpartum depression (PPD). The independent Data Safety Monitoring Board (DSMB) recommended the trial continue without modifications, reporting no serious adverse events among the participants. With ongoing enrollment and a successful safety profile, Lipocine is set to release topline results in the second quarter of 2026, potentially paving the way for a new treatment option in PPD. The company aims to file a New Drug Application based on the trial data in 2026.
Read more →LPCNLipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine Inc. has announced that its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression (PPD), has reached 80% enrollment. The trial, which has received positive feedback from the FDA, is being conducted entirely in an outpatient setting. The results are expected to support a 505(b)(2) NDA submission in 2026.
Read more →LPCN▲ +12.7%on this news
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Inc. has reported positive interim results from its Phase 3 trial of LPCN 1154 for postpartum depression. An independent Data Safety Monitoring Board review confirmed no serious adverse events and recommended the trial continue as planned. The trial aims to evaluate LPCN 1154's safety and efficacy in women diagnosed with severe postpartum depression, with results expected in 2026.
Read more →LPCNLipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine reported a net loss of $3.2 million for the third quarter ended September 30, 2025. The company held $15.1 million in unrestricted cash and marketable investment securities at the end of the period. Royalty revenue from TLANDO sales reached $115,000 during the quarter. Research and development expenses increased to $2.7 million compared to the prior year period.
Read more →About Lipocine Inc.
Headquarters675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, X1, 84108
BIOPHARMAWATCH ELITE PLUS
Trade the next LPCN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime